It might take a while for this AI company to prove its worth, if it ever does so. Recursion Pharmaceuticals (RXRX 2.83%) is a small-cap biotech with a mission. Last year, Recursion Pharmaceuticals' shares fell significantly. One of Recursion Pharmaceuticals' long-term goals is to license its AI models to other drugmakers once it proves the value of its approach. Will Recursion Pharmaceuticals bounce back this year?